Modelling the economic and health consequences of cardiac resynchronization therapy in the UK

Current Medical Research and Opinion

Volumn 22, Issue 6, 2006, Pages 1171-1179

  Caro, J Jaime ^a,b   Guo, Shien ^a,c   Ward, Alexandra ^a   Chalil, Shajil ^d   Malik, Farzana ^e   Leyva, Francisco ^d  

^a CARO RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c SAINT LOUIS UNIVERSITY   (United States)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e Medtronic Sarl ^*  (Switzerland)

Author keywords

Cardiac resynchronization therapy; Cost effectiveness; CRT; Economics; Heart failure; UK

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEATH; DEMOGRAPHY; ECONOMIC ASPECT; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; QUALITY ADJUSTED LIFE YEAR; REDUCTION; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; UNITED KINGDOM; VALIDATION PROCESS;

CARDIAC PACING, ARTIFICIAL; COST-BENEFIT ANALYSIS; DEFIBRILLATORS, IMPLANTABLE; GREAT BRITAIN; HEART FAILURE, CONGESTIVE; HUMANS; MODELS, ECONOMIC; PREDICTIVE VALUE OF TESTS;

EID: 33745685708     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X112516     Document Type: Article

References (33)

1. British Heart Foundation Statistics. Coronary heart disease statistics: heart failure supplement 2002. Available from http://www.heartstats.org/ homepage.asp/ [last accessed 17 Feb 2006]
2. British Heart Foundation Statistics. Deaths from heart failure, by sex and age and country, 2001, UK. Available from http://www.heartstats.org/ homepage.asp/ [last accessed 17 Feb 2006]
3. Lacey L, Tabberer M. Economic burden of post-acute myocardial infarction heart failure in the United Kingdom. Eur J Heart Fail 2005;7:677-83
4. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235
5. Swedberg K, Cleland J, Dargie H, et al. ESC 2005 guideline for the diagnosis and treatment of chronic heart failure. Available from: http://www.escardio.org/NR/rdonlyres/8A2848B4-5DEB-41B9-9A0A-5B5A90494B64/0/ CHFFullTextehi205FVFW170505.pdf/ [last accessed 19 March 2006]
6. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New Engl J Med 2004;350:2140-50
7. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. New Engl J Med 2002;346:1845-53
8. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002;40:111-8
9. Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002;39:2026-33
10. Braunschweig F, Linde C, Gadler F, Ryden L. Reduction of hospital days by biventricular pacing. Eur J Heart Fail 2000;2:399-406
11. Banz K, Eucomed CRT Steering Committee. Cardiac resynchronization therapy (CRT) in heart failure - a model to assess the economic value of this new medical technology. Value Health 2005;8:128-39
12. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med 2005;352:1539-49
13. Cleland JG, Daubert JC, Erdmann E, et al. The CARE-HF study (Cardiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail 2001;3:3481-9
14. Cleland JGF, Daubert JC, Freemantle N, et al. Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail 2005;7:243-51
15. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005;23:323-32
16. McEwan P, Baboolal K, Conway P, Currie CJ. Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom. Clin Ther 2005;27:1834-46
17. Guest JF, Cookson RF. Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999;15:597-610
18. Cooper K, Davies R, Roderick P, et al. The development of a simulation model of the treatment of coronary heart disease. Health Care Manag Sci 2002;5:259-67
19. McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006;22:121-9
20. Bozzette SA, Boer R, Bhatnagar V, et al. A model for a smallpox-vaccination policy. New Engl J Med 2003;348:416-25
21. Davies R, Roderick P, Canning C, et al. The evaluation of screening policies for diabetic retinopathy using simulation. Diabetic Med 2002;19:762-70
22. Kelton WD, Sadowski RP, Sadowski DA. Simulation with ARENA, 3rd ed. Boston: McGraw-Hill; 2003
23. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan [Pimobendan Multicenter Research Group]. Am Heart J 1992;124:1017-25
24. Calvert MJ, Freemantle N, Cleland JGF. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail 2005;7:243-51
25. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
26. National Institute of Clinical Excellence. Guide to the methods of technology appraisal (N0515). Available from http://www. nice.org.uk/pdf/ TAP_Methods.pdf/ [last assessed 11 Oct 2005]
27. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. Br Med J 2004;329:224-7
28. Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail 2005;26:2681-8
29. Feldman AM, deLissovoy G, Bristow MR, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005;46:2311-21
30. Lewis EF, Johnson PA, Johnson W, et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001;20(9):1016-24
31. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65-75
32. Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J 2006;151:444-50
33. Middel B, Bouma J, de Jongste, et al. Psychometric properties of the Minnesota Living with Heart Failure Questionnaire (MLHF-Q). Clin Rehabil 2001;15:489-500